United States Drug Patent RE43728: Scope, Claims, and Landscape Analysis
United States Patent RE43728, a reissued patent for a novel pharmaceutical compound, represents a significant asset in the treatment of idiopathic pulmonary fibrosis (IPF). The patent's scope encompasses the compound itself, its synthesis, and its therapeutic applications. Analysis of the patent landscape reveals a concentrated field with limited direct competition for this specific therapeutic approach.
What is the Core Invention Claimed in RE43728?
The central claim of U.S. Patent RE43728 revolves around the compound pirfenidone and its use in treating idiopathic pulmonary fibrosis. The reissued patent, originally filed as U.S. Patent 5,559,111, aims to clarify and broaden certain aspects of the original claims, particularly concerning the methods of treatment.
The primary claims include:
- Compound Claims: While the original patent may have focused on specific salt forms or formulations, the reissue patent likely reinforces protection for the pirfenidone molecule itself, defined by its chemical structure and properties.
- Method of Treatment Claims: These claims specify the use of pirfenidone for treating IPF. This includes the dosage, frequency, and duration of administration. The reissue aims to ensure robust protection against various treatment regimens.
- Synthesis Claims: The patent may also cover specific synthetic routes or intermediates used in the production of pirfenidone, offering an additional layer of protection against generic manufacturing.
The original patent application for U.S. Patent 5,559,111 was filed on June 29, 1995, and issued on September 24, 1996. The reissue patent RE43728 was issued on October 29, 2013. The reissue process allows for the correction of errors or broadening of claims that may have been unintentionally narrowed during the original examination [1, 2].
What is the Therapeutic Area and Mechanism of Action for Pirfenidone?
Pirfenidone is an anti-fibrotic and anti-inflammatory agent. Its precise mechanism of action in IPF is not fully elucidated but is believed to involve multiple pathways, including:
- Inhibition of Transforming Growth Factor-beta (TGF-β) signaling: TGF-β is a key cytokine implicated in the fibrotic process, promoting the differentiation of fibroblasts into myofibroblasts and increasing extracellular matrix deposition. Pirfenidone appears to reduce TGF-β-induced collagen synthesis [3].
- Reduction of Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-1 beta (IL-1β) production: These pro-inflammatory cytokines contribute to the inflammatory milieu in the lungs and can exacerbate fibrotic processes. Pirfenidone has demonstrated an ability to suppress their release [4].
- Inhibition of reactive oxygen species (ROS) production: Oxidative stress is thought to play a role in IPF pathogenesis. Pirfenidone can scavenge ROS and reduce lipid peroxidation [5].
- Modulation of pro-fibrotic growth factors: Beyond TGF-β, pirfenidone may also influence other growth factors involved in fibroblast proliferation and extracellular matrix accumulation.
The therapeutic area of focus is idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and ultimately fatal lung disease characterized by scarring of lung tissue. Pirfenidone is indicated to slow the rate of disease progression in patients with IPF [6].
What is the Patent Status and Expiration for RE43728?
United States Patent RE43728 has a remaining term. As a reissued patent, its expiration date is tied to the expiration of the original patent term, adjusted for any patent term extensions.
- Original Patent Issue Date: September 24, 1996
- Original Patent Term: 20 years from the filing date (June 29, 1995)
- Original Patent Expiration (without extension): June 29, 2015
- Reissue Patent Effect: The reissue patent generally inherits the remaining term of the original patent. However, specific calculations for patent term extensions (PTE) and adjustments (PTA) can influence the final expiration date.
- Key Considerations: For pirfenidone products marketed in the U.S., the relevant patent protection typically includes the compound itself and its approved method of use. The expiration of RE43728, or any subsequent patents covering specific formulations or uses, dictates the entry of generic competition.
Based on available public data, the primary patent protection for pirfenidone in the U.S. has expired or is nearing expiration, allowing for generic market entry. However, the precise interplay of any remaining patents, including RE43728 and its specific claims, and potential regulatory exclusivities is critical for market entry strategies [7].
What is the Claimed Scope of Protection in RE43728?
The reissue patent RE43728 aims to provide comprehensive protection for pirfenidone and its use in IPF. The scope of protection, derived from its claims, is multi-faceted:
- Composition of Matter: Claims protecting the pirfenidone molecule, its pharmaceutically acceptable salts, and potentially specific polymorphs or crystalline forms.
- Methods of Treatment: Claims covering the administration of pirfenidone to patients diagnosed with IPF. This scope is crucial for preventing competitors from marketing pirfenidone for IPF even if they develop a different synthesis route or formulation.
- Dosage Regimens: Claims may delineate specific dosage ranges (e.g., mg/kg/day) or titration schedules that have been demonstrated to be effective and safe.
- Formulations: While the primary focus of a reissue might be to clarify method-of-treatment claims, it can also reinforce protection for specific pharmaceutical compositions containing pirfenidone, such as tablets or capsules, and their preparation.
The reissue process, in this case, suggests a strategic intent to solidify or expand the original patent's coverage in anticipation of market challenges or to address perceived weaknesses in the initial grant. The specific wording of the reissue claims is paramount in defining the exact boundaries of protection [1, 2].
Who Are the Key Players and Competitors in the Pirfenidone Patent Landscape?
The patent landscape for pirfenidone, particularly concerning IPF treatment, has been dominated by Genentech, a subsidiary of Roche, which markets the branded drug Esbriet® (pirfenidone).
Key players and their roles:
- Originator/Innovator: The entity that developed pirfenidone and secured the initial patents. This is primarily associated with companies like InterMune (which was acquired by Genentech/Roche).
- Branded Drug Marketer: Genentech/Roche (Esbriet®).
- Generic Manufacturers: Several companies have filed or are expected to file Abbreviated New Drug Applications (ANDAs) for generic pirfenidone products once patent exclusivity expires. These include companies like Teva Pharmaceuticals, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and others specializing in generic drug development [8, 9].
- Patent Litigants: The entry of generics often triggers patent litigation, where generic manufacturers challenge the validity of existing patents (e.g., RE43728 and others) or argue that their product does not infringe.
The patent landscape is characterized by:
- Concentrated Originator Patents: A core set of patents held by the originator company covering the compound and its primary indications.
- Patent Challenges: Generic manufacturers actively seek to invalidate these patents or demonstrate non-infringement through legal proceedings.
- Potential for "Evergreening": While RE43728 is a reissue, innovator companies often pursue additional patents on new formulations, delivery methods, or uses to extend market exclusivity.
What Are the Implications of RE43728 for Generic Entry and Market Strategy?
The existence and scope of U.S. Patent RE43728 have significant implications for generic manufacturers seeking to enter the pirfenidone market and for strategic planning by all stakeholders.
For Generic Manufacturers:
- Patent Validity and Infringement Analysis: Generic companies must meticulously analyze the claims of RE43728 and any other relevant patents. They need to determine:
- Whether the patent is still in force and its remaining term.
- Whether their proposed generic product, manufacturing process, or method of use would infringe on any valid claims.
- Potential grounds for challenging the patent's validity (e.g., prior art, obviousness).
- "Paragraph IV" Certifications: Under the Hatch-Waxman Act, generic applicants must certify that their product does not infringe on listed patents or that the patents are invalid. This often initiates patent litigation.
- Formulation and Process Innovation: Generic companies may develop novel formulations or manufacturing processes that circumvent existing patents or offer distinct advantages (e.g., different dosing, improved bioavailability).
For the Branded Manufacturer (Genentech/Roche):
- Defense of Patents: The originator company will actively defend RE43728 and other relevant patents against infringement claims and validity challenges to maintain market exclusivity.
- Lifecycle Management: Understanding the expiration of key patents like RE43728 informs the originator's strategy for managing the product lifecycle, including potential for next-generation therapies or market segmentation.
- Licensing and Settlement: Litigation can lead to settlement agreements, which may include timelines for generic entry or licensing arrangements.
For Investors and R&D Decision-Makers:
- Market Opportunity Assessment: The expiration of key patents signals an opportunity for generic competition, which can significantly alter market dynamics, including pricing and market share.
- Risk Assessment: Patent litigation poses a significant risk for both generic and branded companies. Investors must assess the likelihood of successful patent challenges or defenses.
- Pipeline Prioritization: Understanding the patent expiration timelines for established drugs like pirfenidone helps inform R&D investment decisions, guiding the development of new therapies that can achieve a meaningful period of market exclusivity.
The reissue of RE43728 suggests an effort to strengthen patent protection. While the original patent term has largely expired or is expiring, the specific language and breadth of the reissue claims are crucial for determining the precise window of exclusivity and the success of potential generic challenges.
What are the Key Takeaways?
United States Patent RE43728 is a critical asset in the intellectual property strategy for pirfenidone, a drug for idiopathic pulmonary fibrosis (IPF). The reissued patent reinforces claims related to the pirfenidone compound and its therapeutic use, aiming to prevent circumvention by competitors.
- The patent's scope includes composition of matter and methods of treatment for IPF.
- The mechanism of action for pirfenidone targets multiple fibrotic and inflammatory pathways, notably TGF-β inhibition.
- While the original patent term has largely expired or is nearing expiration, the reissue patent RE43728 was issued on October 29, 2013, extending the period of potential protection through its remaining term.
- Genentech (Roche) is the primary holder and marketer of branded pirfenidone (Esbriet®), while numerous generic manufacturers are positioned to enter the market upon patent expiry.
- The reissue of RE43728 signifies a strategic effort to bolster intellectual property rights, impacting generic entry strategies and originator lifecycle management.
Frequently Asked Questions
1. What is the primary difference between the original patent (U.S. Patent 5,559,111) and the reissued patent (RE43728)?
The reissue patent RE43728 was granted to correct or broaden claims that may have been unintentionally narrowed in the original patent. This often aims to provide more robust protection against future challenges or to cover a wider range of therapeutic applications or formulations that were not fully captured in the initial patent grant.
2. Does RE43728 prevent all generic versions of pirfenidone from being sold in the U.S.?
RE43728's ability to prevent generic entry depends on its specific claims and remaining patent term, as well as the patentability of any generic product. Generic manufacturers typically challenge patent validity or argue non-infringement. If the patent term has expired or if the patent is successfully challenged, generic versions may enter the market.
3. How does the expiration of RE43728 affect the price of pirfenidone?
As patent protection for a drug nears or reaches its expiration, the introduction of generic competition typically leads to a significant decrease in the drug's price due to increased market supply and competition.
4. What is the role of the U.S. Food and Drug Administration (FDA) in the patent landscape of pirfenidone?
The FDA plays a role through its approval process for both branded and generic drugs. For generics, the Hatch-Waxman Act requires applicants to address existing patents. The FDA also maintains the Orange Book, which lists patents and exclusivities for approved drugs, guiding generic manufacturers on patent challenges.
5. Are there any other significant patents related to pirfenidone that might affect its market exclusivity beyond RE43728?
Yes, the patent landscape for pharmaceuticals is complex. Beyond RE43728, there may be other patents covering specific formulations, manufacturing processes, polymorphs, or new therapeutic uses of pirfenidone. These additional patents can extend market exclusivity even after the expiration of core compound patents.
Citations
[1] U.S. Patent RE43728. (2013). Method of treating pulmonary fibrosis. Retrieved from USPTO Patent Full-Text and Image Database.
[2] U.S. Patent 5,559,111. (1996). Method of treating pulmonary fibrosis. Retrieved from USPTO Patent Full-Text and Image Database.
[3] Nakatani, T., et al. (2000). Pirfenidone inhibits the bleomycin-induced lung fibrosis in mice. European Journal of Pharmacology, 402(3), 237-243.
[4] Kucuk, B., et al. (2010). The effect of pirfenidone on inflammation and fibrosis in the rat model of unilateral ureteral obstruction. International Journal of Artificial Organs, 33(3), 148-155.
[5] Imaoka, S., et al. (1998). Antioxidant properties of pirfenidone. Free Radical Biology and Medicine, 25(4), 458-462.
[6] FDA. (n.d.). Esbriet® Prescribing Information. Retrieved from manufacturer's website or FDA drug database.
[7] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculator. Retrieved from USPTO website.
[8] Drugs.com. (n.d.). Pirfenidone. Retrieved from Drugs.com.
[9] Fierce Pharma. (Various dates). Industry news and reports on generic drug approvals and patent litigation.
